If the laboratory is boosted by its opportunities in Africa in particular, the group remains shaken by soaring costs.
The British pharmaceutical group AstraZeneca saw its sales jump in the first half, but its profits plunged due to a surge in costs linked in particular to the integration of its subsidiary Alexion, it announced on Friday in a press release.
The laboratory recorded a 48% increase in its turnover, to 22.2 billion dollars, over the first six months of the year, and raised its sales forecast for the year. Net profit, group share, fell 64% to $746 million.
SEE ALSO – EDF suffers an exceptional loss of 5.3 billion euros in the first half